Importance

Loading Importance Indicators...

Abstract

The present invention relates to the provision of a medicament and of a diagnostic agent obtained by proteome analysis, preferably containing at least two different chemokine receptor ligands or chemokine receptor antibodies, and further to the use of at least two different chemokine receptor ligands, chemokine receptor antibodies and/or two different chemokine receptors. As inhibitors, the medicament preferably contains ligands or antibodies of at least two chemokine receptors or the related algorithms of the surface chemokine receptor proteome, and the use of at least one chemokine receptor ligand and/or chemokine receptor, peptides and antibodies and their use for the diagnostics and therapy of tumor diseases and inflammatory diseases. By way of analogy, clusters of analyzed tumor cell surface proteomes, such as ectoproteases, adhesion molecules or various receptor types, can also be used. The invention relates to a method for the purpose of diagnosis and therapy and the medical and industrial use of chemokines and their corresponding receptors, their antagonists including antibodies was found to inhibit cancer growth including metastatic spread, and to suppress inflammatory and auto-immune diseases. The method is based on the finding that chemokines act on specific tumor and inflammation cells via autocrine, paracrine and endocrine routes through the disease-specific constellation of the chemokine receptor proteome. Primary and secondary tumors as well as specific inflammation cells are controlled with respect to their migration and proliferation behavior. By diagnostically detecting the chemokines whose expression and regulation is locally increased and the presence of the chemokine receptor compositions, the possibility arises of critically suppressing or completely preventing cancer growth, metastatic spread of tumors as well as inflammatory and auto-immune diseases.

Loading the Abstract Image...

First Claim